Cannabis stocks, including Tilray, plunged after a 2021 speculative peak, remaining in long-term decline. Momentum may shift as U.S. authorities consider reclassifying cannabis. Tilray shows technical...
On August 29th, 2023, the U.S. HHS recommended to the DEA that cannabis be reclassified from a Schedule I drug to a Schedule III drug. Rescheduling...